Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Protheroe

Showing results (51-60 of 83) with videos related to

Pageof 9
Sort By:
The Lancet. Oncology|January 23, 2016
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trialAndrew J Armstrong, Susan Halabi, Tim Eisen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell CarcinomaAndrew J Armstrong, Andrew B Nixon, Andrea Carmack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2021
Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell CarcinomaAndrew J Armstrong, Andrew B Nixon, Andrea Carmack, et al.
European Urology|October 29, 2015
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 StudiesJoaquim Bellmunt, Thian Kheoh, Margaret K Yu, et al.
Kidney Cancer Journal : Official Journal of the Kidney Cancer Association|November 12, 2021
Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trialSusan Halabi, Qian Yang, Andrea Carmack, et al.
Cold Spring Harbor Molecular Case Studies|April 4, 2018
Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencingAnna Schuh, Helene Dreau, Samantha J L Knight, et al.
BMC Cancer|November 19, 2021
The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocolStephan Ursprung, Helen Mossop, Ferdia A Gallagher, et al.
JU Open Plus|March 12, 2026
Flourine-18 Prostate-Specific Membrane Antigen-1007 Positron Emission Tomography Imaging in Staging of Primary and Secondary Prostate Cancer-A Retrospective Observational Cohort StudyMatthew H V Byrne, Nithesh Ranasinha, Abhishek Sharma, et al.
Nature Medicine|June 20, 2020
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trialThomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
Nature Medicine|March 22, 2023
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trialThomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
Pageof 9

Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
The Lancet. Oncology|January 23, 2016
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trialAndrew J Armstrong, Susan Halabi, Tim Eisen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell CarcinomaAndrew J Armstrong, Andrew B Nixon, Andrea Carmack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2021
Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell CarcinomaAndrew J Armstrong, Andrew B Nixon, Andrea Carmack, et al.
European Urology|October 29, 2015
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 StudiesJoaquim Bellmunt, Thian Kheoh, Margaret K Yu, et al.
Kidney Cancer Journal : Official Journal of the Kidney Cancer Association|November 12, 2021
Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trialSusan Halabi, Qian Yang, Andrea Carmack, et al.
Cold Spring Harbor Molecular Case Studies|April 4, 2018
Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencingAnna Schuh, Helene Dreau, Samantha J L Knight, et al.
BMC Cancer|November 19, 2021
The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocolStephan Ursprung, Helen Mossop, Ferdia A Gallagher, et al.
JU Open Plus|March 12, 2026
Flourine-18 Prostate-Specific Membrane Antigen-1007 Positron Emission Tomography Imaging in Staging of Primary and Secondary Prostate Cancer-A Retrospective Observational Cohort StudyMatthew H V Byrne, Nithesh Ranasinha, Abhishek Sharma, et al.
Nature Medicine|June 20, 2020
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trialThomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
Nature Medicine|March 22, 2023
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trialThomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
Pageof 9